On the afternoon of November 6, Invest Shenzhen, together with the "Science Bridge" biomedical platform, held the “Shenzhen Biological and Life Health Industry Development Exchange Symposium” in Room 1209 at the agency’s offices. The conference leveraged the opportunities of the large-scale investment cooperation between China and Europe and served as part of its 2018 annual bio-health industry project development work to invite biological and life health industry experts, representatives from key companies and industry investment experts to attend the conference. The main guests included executives from German companies Fresenius Kabi and the Merck Group, AstraZeneca from the UK, the Institute of Health Sciences at the Chinese Academy of Sciences, Gihon Biotech Limited from Hong Kong and the Shenzhen Association for Health Industry Development. Also invited were officials from Invest Shenzhen – Yantian District Center, Dabaihui Group, China Construction Bank and Huaxia Bank.
At the meeting, bio and life health industry experts and business representatives held discussions on establishing projects and industrial development, and put forward their suggestions and opinions on the investment strategy of Shenzhen’s biological and life health industry.